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Abstract
Purpose During the last five decades drug and therapeutics
committees (DTCs), have evolved from mainly hospital-
based groups of experts in pharmacotherapy and drug logis-
tics into an arena for healthcare professionals employing
evidence-based methods of promoting rational drug use.
The purpose of this study was to suggest a framework for
analysing the structure and activities of DTCs.
Methods A literature search was carried out in the Medline,
Cinahl and Web of Sciences databases for the period 1993–
2012.
Results A total of 207 articles were included. Based on
these articles a framework for the analysis of the DTCs
based on the role of the DTC, target groups, budget per-
spective and type of economic decisions could be
suggested.
Conclusions In order to respond to future demands the DTCs
will have to develop their skill in pharmacoeconomics. Their
processes will have to be standardised and made more trans-
parent in order to be better adapted to evidence-based deci-
sion-making. They will also have to embrace the possibilities
created by electronic health records in both influencing the
decisions of physicians, and in improving quality assurance
programmes and longitudinal follow-up of drug therapy and
outcomes. They will have to find newways of interacting with
the public and policy makers in order to get the resources
needed for their work. Finally, they will have to handle the
conflict among national, regional and local decision-making
processes and the relationship between formularies and ther-
apeutic guidelines.
Keywords Drug and therapeutics committee . Pharmacy
and therapeutics committee . Prioritization . Cost-effective
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Abbreviations
APC Area Prescribing and Medicine Management
Committees
ASHP The American Society of Health System
Pharmacists
CPOE Computerised order entry systems
DTC Drug and Therapeutics Committee
EBM Evidence-based medicine
IUPHAR The International Union of Basic and Clinical
Pharmacology
MeSH Medical subjects heading
P&T
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Pharmacy and Therapeutics Committee
Introduction
For the prescriber, time is scarce. There is an overload of
information about new treatment options employing old and
new drugs, and even new information about old drugs. For
providers of healthcare there are new, often more effective,
but also more costly, drugs to consider. Meeting the costs of
these drugs given local budget constraints and silo budgets
is a challenge. At the same time, there may be opportunities
to reduce drug costs through procurement, generic substitu-
tion, and in some instances therapeutic substitution [1].
Information about drugs and other treatment options is
more abundant and easier to access today than ever before.
For the patient, there are concerns about the quality of care
and access to new treatment options, and about being able to
pay for a more expensive drug. In addition, on-going efforts
are being made to empower the patient, making him or her
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more involved in the decision making process in the health-
care system.
Some—but not all—of the present day challenges were
also present more than half a century ago when the fore-
runners of today’s drug and therapeutics committees were
formed. The first modern drug and therapeutics committee
(DTC) in Sweden was formed in 1961 at the Karolinska
Hospital in Stockholm [2]. The establishment of this first
formal DTC in Sweden coincided with the introduction of
clinical pharmacology [3–6] as a medical specialty in the
late 1950s, and the DTCs very soon became a hub for the
exchange of ideas and knowledge among physicians, clini-
cal pharmacologists and pharmacists.
A drug and therapeutics committee, or as it is also often
called, a pharmacy and therapeutics committee, can be defined
in different ways. According to the WHO the goal of a DTC is
“to ensure that patients are provided with the best possible cost-
effective and quality of care through determining what medi-
cines will be available, at what cost, and how they will be used”
[7]. The American Society of Health System Pharmacists
(ASHP) has stated that “the P&T committee should serve in
an evaluative, educational, and advisory capacity to the medical
staff and organisational administration in all matters that pertain
to the use of medications (including investigational medica-
tions)” [8]. The definition of the MeSH term Pharmacy and
Therapeutics Committee is narrower: “An advisory group
composed primarily of staff physicians and the pharmacist
which serves as the communication link between the medical
staff and the pharmacy department” [9]. The emphasis in this
definition is on hospitals and not on collaboration among different
healthcare providers and pharmacies within a geographical area.
Pharmacy and Therapeutics Committee is a term that is also
used, especially in the USA, as the name of a committee man-
dated by law or by local regulation to either decide upon, or to
recommend to a deciding body, which of the drugs that are to be
made available will also be covered by insurance or a benefit
scheme within an organisation or a state. This review focuses on
the role of the DTCs within the healthcare system that mainly
play a supportive role as defined by the WHO [7].
The purpose of this article is to propose a framework in which
the organisation and activities of DTCs can be analysed in
different settings. The nature of the framework is based on a
narrative reviewof the evolution of the organisations and goals of
DTCs during the last half-century as a consequence of changes
both in healthcare systems and in the role of the prescriber.
Materials and methods
A literature search was performed in the Medline, Cinahl and
Web of Science databases from 1993 to 2012. For Web of
Science and Cinahl all studies with the text “pharmacy and
therapeutics committees”OR “drug and therapeutic committees”
OR “medicines and therapeutics committees”were included. For
Medline, studies indexed under the MeSH terms “pharmacy and
therapeutics committee” OR “hospital formularies” were also
included.
The search included studies of DTCs published in English,
French, Spanish, German and the Scandinavian languages
(Swedish, Danish and Norwegian). Studies in other languages
with an abstract in English could be eligible for translation and
inclusion if they included outcome measures relevant to the
review. No study fulfilled these criteria.
Relevant references in published articles fulfilling the search
criteria were added. Articles focusing on committees that make
decisions or that act as advisors to deciding bodies as regards
inclusion in reimbursement schemes and/or insurance coverage
were excluded in order to focus on DTCs with a supportive role.
Studies were classified by the author according to type
(study, editorial/opinion piece, definition/statement), and fo-
cus of the article (goal, organisation of the DTC, interaction
with the healthcare organisation, decision-making process,
and/or ways of influencing the use of drugs). No independent
validation of this selection process was performed.
Results and discussion
The total number of studies identified was 811 in Medline,
269 in Web of Science and 120 in Cinahl. After a manual
search of the articles a total of 192 articles—108, 83 and 19
from the different sources – were found relevant to the topic
of this review. None of the studies included from Cinahl
overlapped with those from the other two sources. In addi-
tion 15 relevant articles cited in the reference lists of articles
studied were added.
The decision to start a DTC or to expand the activities of
an existing DTC can be seen as a multi-modal intervention,
often triggered by events in the society that could act as
confounders. To start a DTC is a strategic decision in the
healthcare setting, often being just one of many different
activities initiated at the same time. As a consequence, it is
hard to establish a credible control group, or to use historical
data as a control, when evaluating the effects of DTCs.
It is thus not surprising that no controlled evaluations of the
effects of establishing a DTC on outcomes such as the quality
or the cost-effectiveness of health care were found. On the other
hand, studies and structured reviews of the effect of various
tools used by DTCs in order to influence drug utilisation are
common, but these lie outside the scope of this review
Studies of approaches to influencing the behaviour of
decision-makers, for instance, prescribers, show that a sim-
ple transfer of information will seldom change their behav-
iour. In order to achieve such changes, the attitudes towards
the problem and/or the alternative solutions frequently have
to change. This is a well-known issue within health
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promotion [10–12]. Questions like what kind of problem it
is, whose problem it is, what the magnitude of the problem
is etc. are important determinants for changed behaviour.
Similarly, attitudes towards the solutions such as perception
of the size of the effect (including the use of absolute versus
relative risk reductions), handling of uncertainty, the per-
ception of drugs as an intervention in a multifactorial dis-
ease, etc. are important factors that can influence the
decision-making process by physicians.
Many other factors, among them the extent to which
the patient is involved in the decision-making process,
perceived or real peer pressure, expectations of the
patient, the role of the physician in society, marketing,
economic incentives for the prescriber, can also influ-
ence decision-making. Thus, influencing attitudes among
individual and groups of prescribers as regards one or
more factors may be seen as avenues leading to changes
in the ultimate decision.
Educational outreach visits or academic detailing is a meth-
od of knowledge transfer that may be used to influence atti-
tudes among prescribers. A Cochrane review of 69 studies
concluded that educational outreach visits appeared to im-
prove the care delivered to patients [13]. Such visits consis-
tently led to small changes in prescribing. For other types of
professional practice, such as providing screening tests, out-
reach visits provided small to moderate changes in practice.
Goal of a DTC
The WHO emphasises the supportive role of a DTC by
describing DTCs as forums for the development and imple-
mentation of appropriate medicine policies where all the
relevant professionals can work together to improve
healthcare delivery, whether in hospitals or other health
facilities [7]. Even though the WHO promotes the DTC as
an integral element in the development of rational guidelines
for the use of medicines [14, 15], the number of reports on
DTCs in the developing world appearing in the scientific
databases searched is still small.
The goals set for DTCs have changed over time. At first the
goal was simply to find solutions to basic logistic problems;
now, there can be many goals including technology assess-
ment, cost-effectiveness analysis, and the addressing of issues
concerning patient safety [16]. Different needs arise in differ-
ent contexts; in one setting the primary goal can be cost
containment, in another the setting of priorities in healthcare
systems [17–19]. If setting priorities is a primary goal then
healthcare providers, physicians and patients must have
criteria for responding to the decisions or recommendations
from a DTC. A common criterion for setting priorities in
healthcare is “fairness”. The question “How is fairness to be
evaluated” must then be dealt with. An example of this is the
concept of “accountability for reasonableness” developed by
US Health Maintenance Organizations to specify the condi-
tions for operationalising the concept of fairness [19].
Studies of the role and goals of a DTC have shown a
wide range of views, sometimes even within one country
[20–22]. This is to be expected depending on the choice of
the target group, which might in one setting be the
healthcare provider and in another the needs of a specific
patient population.
Organisation: structure and mandate
A literature review of studies published between 1997 and
2008 on the structure and operation of hospital-based
DTCs in nine western countries was identified. Some stud-
ies were concerned with the structure and operation of
DTCs (n=9) and others with factors that influence deci-
sions made by DTCs (n=8) [23]. This review is concerned
only with hospital-based DTCs in six countries (USA, The
Netherlands, UK, Canada, Germany and Belgium)
[24–32]. The structure and operating procedures of the
DTCs in these countries were similar. With the exception
of Germany, nearly all hospitals had both a DTC and a
formulary. In the USA 84 % of hospitals had therapeutic
interchange programs [1, 33, 34] while the corresponding
figure for Germany was only 36 %. In a study from Spain
that was not included in the review 71 % of the hospitals
reported having a therapeutic interchange program [35].
Hospital-based or population-focused
Misunderstandings and problems with drug treatment often
occur at the interface between different healthcare providers.
Many patients receive healthcare, and thus also drugs, from
different providers. Drugs initiated in specialist units are con-
tinued in primary care, while drugs prescribed from primary
care are continued during treatment episodes at hospitals. The
need for coordination between different healthcare providers
has led to a population-focused goal, taking responsibility for
all people in a defined geographic area, for DTCs, for in-
stance, in the Nordic countries [2], and to the development
of specific coordinating committees such as Area Prescribing
and Medicine Management Committees (APC) in the UK
[36]. An APC is essentially an intermediary committee be-
tween national/regional decision makers and local hospital-
based DTCs with the goal of ensuring a consistent health
community approach to medicines management.
The structure of DTCs
A typical DTC consists of physicians (specialised in inter-
nal medicine or any other drug-intensive specialty), nurses
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and pharmacists [23]. The base from which members can
be recruited has widened over time as formularies have
evolved from very limited lists of drugs into comprehen-
sive documents or programs describing complete systems
of medication use policies intended to ensure safe, appro-
priate, and cost-effective use of pharmaceuticals in patient
care [37]. A DTC can now include representatives from
administration, quality assurance groups, other healthcare
professionals and also representatives from user organisa-
tions [38, 39].
In DTCs with a population-focused approach (i.e. having
responsibility for improving the use of drugs for all people
in a defined geographic area) general practitioners are often
included both in the DTC itself and in relevant subcommit-
tees. In addition, other professionals such as clinical phar-
macologists, epidemiologists, ethicists, administrators
and/or health economists may be included [40].
Representatives from user organisations may also be a part
of a DTC in order to capture patient perspectives on drug
treatment, provide for better interaction with patient groups
about decision making, and to increase the credibility of the
DTC among patients and politicians.
Even though pharmacoeconomic considerations have
long been described as important for DTCs [40–44] there
are several factors that have impeded the application of
pharmacoeconomic methods, not least of which is a lack
of training in health economics and in the availability of
health economists [40, 45].
Two particularly important professional groups repre-
sented in a DTC are the pharmacists and the clinical phar-
macologists. A statement from American Society of Health
System Pharmacists describes in detail the pharmacist’s
responsibilities and roles in managing the formulary system
in partnership with other healthcare professionals, but with a
focus on DTCs in hospitals [37].
The clinical pharmacologist is a physician who has had
systematic training in the evaluation of drug therapy and
drug products. The International Union of Basic and
Clinical Pharmacology, IUPHAR, has stated that participa-
tion in DTCs is a key role for clinical pharmacologists, since
these bodies provide a basis for implementing the principles
of the rational prescribing of drugs. According to the
IUPHAR, clinical pharmacologists also have a responsibil-
ity for training DTC members in critical drug evaluation and
ensuring that drug recommendations are based on scientific
evidence and medical needs as assessed by independent
drug experts in various pharmaco-therapeutic areas [3].
Inter-professional collaboration
One of the strengths of a DTC is that it facilitates a multi-
professional approach through which physicians, nurses,
pharmacists and administrators can meet to discuss drug-
related questions and policies from different perspectives.
This approach can lead to both satisfaction and frustration
depending on how the inter-professional relationships de-
velop and are handled by the organisation. The addition of
specialists in epidemiology, logistics and/or health econo-
mists, as well as patient representatives, may enrich but also
complicate the work process. A study of inter-professional
relationships in DTCs in the USA showed that the relation-
ships tended to be rated positively and that members tended
to be quite willing to cooperate with one another. Low levels
of frustration and anger were reported [46].
In 1993 the National Corporation of Swedish Pharmacies
commissioned a survey of the attitudes towards different
sources of drug information among general practitioners in
five counties in Sweden [47]. Among general practitioners,
information from representatives of pharmaceutical compa-
nies was the only kind of information about drugs that was
ranked lower than the information provided by the DTCs.
One Swedish DTC, the Örebro County DTC was, however,
identified as being particularly successful in providing in-
formation. An in-depth analysis showed that among the
success factors of this DTC was the organisational structure
with a network consisting of therapeutic subcommittees,
general practitioners represented as members on all levels,
evidence-based recommendations, emphasis on the support-
ive role of the recommendations, and academic detailing
[48]. Several DTCs in Sweden were reorganised as a con-
sequence of the report.
Mandatory or voluntary
Local and regional DTCs, including APCs, have developed
out of a defined local need to collaborate in order to improve
the practice of drug procurement and logistics, always with
the goal of supporting cost minimisation and safer handling
of drugs. These committees, which more or less fulfil the
WHO definition of a DTC, are normally non-mandatory as
opposed to mandatory national (or in some instances regional)
committees with the goal of deciding whether or not a specific
drug should be included in a formulary and thus be covered by
the pharmaceutical benefit scheme, or by a specific health
insurance scheme.
In 1997 the Swedish Drug Reform Act included a law
making it mandatory for each of the 21 counties to have at
least one DTCwith a population-focused approach that would
support hospital specialists and general practitioners, as well
as physicians at outpatient clinics regardless of the type of
provider organisation. As a consequence of the law the DTCs
were not only given proper resources for performing analyses
and interacting with prescribers, they were also given an
official role within the healthcare organisations.
The counties are also required to provide a budget to
support the activities of the DTC. In the most progressive
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counties the budget constitutes approximately 1 % of the total
cost of the pharmaceutical benefit scheme [2]. The law spec-
ifies that expertise from both medicine and the pharmaceutical
area is to be drawn upon by the DTC and that the DTC should
have access to detailed drug utilisation statistics through the
National Corporation of Swedish Pharmacies. Since July
2010 the counties, and thus also the DTCs, have by law access
to amonthly file of all of the drugs dispensed to the inhabitants
of each county. An encrypted personal identification number
makes it possible to link the dispensation of drugs to data from
electronic health records and/or administrative databases for
quality assurance purposes without the specific consent from
ethical committees for research purposes.
National, regional or local
The need for implementation of mandatory and properly
financed DTCs in Sweden has led to a discussion in society
concerning the risks that might arise from multi-level
decision-making regarding introduction of new drugs. The
pharmaceutical industry and representatives from the na-
tional authorities have questioned the need for the current
legislation, claiming that local decision-making processes
simply waste resources and lead to inequalities in the pro-
vision of healthcare.
The counter-arguments from the healthcare system, and
from the DTCs themselves, have been that local structures
in the society and the healthcare system, and the absence of
unbiased information will always lead to inequalities. Since
DTCs are important actors in detecting and addressing such
situations within the field of pharmaco-therapy the argument
goes that they are in fact needed to counter such inequalities.
In addition, in order to be effective in changing behaviour in
a desired direction it is argued that some of the most crucial
success factors are the existence of a local affiliation and a
clear mandate with proper resources allocated.
Similar discussions have taken place in other countries.
The need for rapid action, awareness of local circumstances
and local safety problems, local pricing arrangements as a
consequence of procurement, affordability for the local or-
ganisation as a complement to considerations of marginal
cost-effectiveness analysis have all been presented in the
UK as reasons for supporting the existence of DTCs with
locally adapted formularies [49]. Other arguments, based on
the available evidence of the existence of effective methods
for changing the behaviour of prescribers, are that dialogue
is better than providing a one-way information process, that
credibility can be increased through the use of local opinion-
leaders, and that the involvement of peers can aid in the
adaptation of national guidelines for the local setting.
Another common argument against local DTCs is the
perceived waste of time that results if the same evidence is
assessed twice, both nationally and locally. The counter-
argument from local organisations is that local specialists
in a disease have to study national guidelines and the evi-
dence on which these guidelines are based, whether or not
they participate in a local expert subcommittee. For this
reason, it makes sense to give them the possibility of par-




Promoting rational prescribing is in itself a process that
depends on an evidence-based approach both to the
decision-making process and to the interventions employed
in order to change the behaviour of physicians [50].
Evidence-based medicine (EBM) has been promoted as a
very important part of the work of a DTC [14]. Still, the
process itself is not always as transparent and rigorous as is
commonly associated with the term EBM. There might be
many reasons for this, such as time constraints and lack of
resources, but the absence of a specific process for decision-
making may contribute to these concerns. In a qualitative
study of the decision-making process in two DTCs in the
UK it was found that EBM, while used in decision making,
was supplemented by local knowledge about other factors,
although decisions were framed in the language of scientific
rationality [51].
Pharmacoeconomics
The cost of drugs has been a core issue from the time of the
first DTCs. Over time there has been an increasing demand
for the full consequences of drug use to be described, not
only in terms of cost minimisation, but also in cost-
effectiveness as a consequence of changing goals and roles
for the DTCs. A thorough knowledge of health economics is
needed in order to assess the marginal benefits of one drug
versus the alternatives, and to compare this with the mar-
ginal net cost. Studies have indicated that evaluation of cost-
effectiveness in decision-making has been limited by com-
mittee members’ lack of specific training, and by the diffi-
culty of applying pharmacoeconomic studies to actual
clinical practice [40, 52].
One important aspect of pharmacoeconomics is the per-
spective of the analysis, whether the analysis is made from
a societal perspective, taking into account all relevant
benefits and costs in society, or from a narrower perspec-
tive, such as that of the payer or the person responsible for
the hospital budget. The choice of perspective depends on
the role of the DTC (Table 1), where the trend over time
has been a movement from cost minimisation in the
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healthcare system in the upper-left corner towards margin-
al cost-effectiveness from a societal perspective in the
lower-right corner.
Changing behaviour
A DTC can be primarily supportive, for instance by giving
advice, or restrictive, i.e. making decisions that are more or
less compulsory for physicians and nurses to follow. It is more
likely that they will be a combination of both. In addition, the
target group for one DTC can differ from that of another,
Table 2. Even in a healthcare setting with similar goals for
the DTCs, factors such as whether drug budgets are devolved
or not can result in different DTCs taking different positions.
In a case study of a county in Sweden with a fully devolved
drug budget it was shown that the DTC had positioned itself as
purely supportive by developing indicators, but abstaining
from setting direct targets for prescribing. Instead, the DTC
required each department to set its own targets together with
prescribers, arguing that each unit was responsible for the
cost-effectiveness and quality of its own prescribing. In an-
other county without devolved drug budgets the DTC was
active in setting prescribing targets linked to economic in-
citements, and thus to a degree restricting physicians’ freedom
to make their own decisions [53].
So-called “soft regulations” are often used in order to
influence the use of drugs. These interventions can typically
be categorised as being based on education, engineering,
economics and enforcement, or the four “Es” [10, 53]. There
are several studies and reviews analysing the effectiveness,
or lack of effect, of different interventions aiming at chang-
ing the behaviour of physicians, but reviewing these studies
is outside the scope of this article.
Education
Providing information, including educational outreach, is a
mainstay in the efforts of most DTCs to influence behaviour.
Providing traditional information in the form of newslet-
ters and group workshops is still considered a natural
basis for other more advanced interventions even though
providing traditional information is not deemed effective
per se. More interactive strategies such as academic
detailing, also called educational outreach, have been
shown to be an effective way of influencing prescribing
behaviour [13]. One important decision for the DTC is to
decide how to balance between “push” and “pull” in
their activities. One option for the DTC is to try to
change attitudes, and thus behaviour, by providing infor-
mation or by initiating activities, that is, by “pushing”.
Another option is to support making structured informa-
tion generally available, setting up quality assurance pro-
jects, and developing clinical decision support systems to
be used when deemed necessary by physicians, that is by
“pulling”.
One example of the push–pull dilemma is the han-
dling of drug statistics. Drug statistics often focus on
reports with feedback on performance including pre-
scribing targets. Another option is for the organisation
to construct a system where the prescribing physicians
can self-monitor their prescribing habits, bench-mark
themselves relative to their chosen peers, and analyse
their prescribing themselves. The balance between the
push and pull alternatives depends on whether or not
there are other structures, such as, for instance, tradition
or devolved drug budgets, that might stimulate action
from the prescribers and thus make “pull” more
efficient.
Physicians are influenced by patients’ perceptions about,
and interest in, new drugs. One way for the DTCs to use this
is to engage in patient-orientated educational activities
designed to help patients develop a better understanding of
the benefits and risks of treatment alternatives, thus
influencing the physicians.
Engineering
Formularies, especially formularies directly linked to gener-
ic substitution, therapeutic interchange or procurement and
thus availability of drugs, can be the basis for strong
Table 1 A simple 3-by-3 table illustrating the different roles of a Drug
and Therapeutics Committee (DTC) for different groups of prescribers















Table 2 A combination of different perspectives and methods can be
employed in pharmacoeconomics. Some of the most important for
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interventions, since they are easy to communicate and fol-
low up, and since in some instances they are mandatory by
law. An important measure in order to make full use of such
an intervention in the hospital setting is a strategy for de-
veloping a drug logistics program that will ensure continued
availability of recommended drugs and making it easier for
the physicians to be compliant.
Factors that influence the physician at the point of decision-
making are in general also effective interventions. Two such
factors are strategies for seeing to it that the physician uses
computerised order entry systems (CPOE) and availability of
computerised clinical decision support systems. These can
interact with the results of procurement of drugs, drug logis-
tics and guidance. Using electronic health records can ensure
that data can be collected in quality registers and be used for
specific local quality indicators. Horizon-scanning for
changes in the drug market is important in order to estimate
what resources will be needed to handle the introduction of
new drugs. An ordered introduction based on the results from
horizon-scanning can make it easier for truly innovative and
valuable new drugs to be introduced to, and used by, the right
patients. This can also help restrict the use of drugs that are
neither innovative nor cost-effective.
Limiting the marketing activities of pharmaceutical com-
panies is a common intervention, but can slow down diffusion
of innovation. Thus, if limits are to be placed on information
activities provided by drug companies then systems for pro-
viding unbiased information about drugs must be developed
and given proportionately greater support.
Economics
Setting targets for prescribing (ratios or volumes) is a com-
mon intervention done by DTC. The aim can be either cost-
minimisation or cost-effectiveness, but it may also include
setting quality indicators as part of a quality assurance
project [54, 55].
Other examples of interventions by DTCs within eco-
nomics are assistance in the procurement of drugs, and
support in drug budget devolution.
Enforcement
One example of enforcement is the monitoring of prescrib-
ing of restricted drugs against agreed guidance with addi-
tional interventions if required. Other examples are deciding
on mandatory guidelines for drug handling at wards.
Conclusions: the future of the DTC
The DTCs have managed to evolve in response to different
demands from healthcare by adopting and endorsing evidence-
based medicine, pharmacoeconomics, pharmacoepidemiology
and employing evidence-based methods of influencing
physicians in order to achieve a more rational drug
use. At the same time they have in many cases managed
to change the physicians’ perceptions of drug formular-
ies from being “cook-book medicine” to an evidence-
based starting point for choosing the right drug for the
right patient. This has been made possible through the
creation of an arena where different professions involved
in the safety, effectiveness and cost-effectiveness of drug
therapy can interact. In Sweden, Professor Folke Sjöqvist
has been both a catalyst and facilitator for the develop-
ment of the DTCs and for developing a clear role for
clinical pharmacology in their processes and his career
has spanned the whole development of the current
Swedish DTCs.
In order to respond to future demands the DTCs will
have to develop their skill in pharmacoeconomics and
implement it in their processes. Their processes will have
to be standardised and made more transparent in order to
be better adapted to evidence-based decision-making.
They will also have to embrace the possibilities created
by electronic health records in both influencing the de-
cisions of physicians and improving quality assurance
programs and longitudinal follow-up of drug therapy and
outcomes with the assistance of pharmacoepidemiology.
They will benefit from finding new ways of interacting
with the public and policy makers in order to get
the resources needed for their work (Fig. 1). Finally,
they will have to handle the conflict among national,
regional and local decision-making processes and














Fig. 1 Established relations between the Drug and Therapeutics Com-
mittee (DTC) and different actors. Dotted lines represent additional,
less frequently described, interactions
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Fact sheet The goal of a DTC according to WHO [7] is to
ensure that patients are provided with the best possible cost-
effective and quality of care through determining what med-
icines will be available, at what cost, and how they will be
used. In order to achieve this goal a DTC will have the
following objectives:
& To develop and implement an efficient and cost-effective
formulary system that includes consistent standard treat-
ment protocols, a formulary list and formulary manual
& To ensure that only efficacious, safe, cost-effective and
good quality medicines are used
& To ensure the best possible drug safety through monitor-
ing, evaluating and thereby preventing, as far as possible,
adverse drug reactions (ADRs) and medication errors
& To develop and implement interventions to improve med-
icine use by prescribers, dispensers and patients; this will
require the investigation and monitoring of medicine use.
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